Collagen N-Telopeptide, Cross-Linked, Urine

• Creatinine, Urine
• N-Telo/Creat. Ratio
• N-Telopeptide

Evaluation of osteoporosis and assessment of antiresorptive therapy.

Specimen Type: Random Urine (Second-Morning Void)

Collection Container: Plastic Urine Container (Preservative Free) 

Desired Specimen Volume: 20 mL

1. Collect random urine (second-morning void) in a plastic urine container (preservative free).
2.  When monitoring therapy, baseline samples should be collected prior to initiation of therapy. 
3. Subsequent specimens should be collected at the same time of day as baseline specimens.

1. Submit 20 mL of random urine (second-morning void) in the original collection container.

Transport to the laboratory refrigerated. 

• Quantity not sufficient for analysis
• Whole blood contamination
• Hemolysis
• Specimen containing preservative

 See patient report.

This test has not been established to predict development of osteoporosis or future fracture risk.

Values obtained with different assay methods should not be used interchangeably in serial testing. It is recommended that only one assay method be used consistently to monitor each patient's course of therapy.

• Collagen Cross-linked N-Telopeptide
• N-Telopeptide
• NTx Test
• Osteomark®